Bridging the gap in pre-market immunological evaluation: a progressive strategy for recombinant collagen medical devices

Abstract

Conventional immunotoxicological approaches are often insufficient to comprehensively elucidate the complex immune responses that may arise during the degradation, metabolite generation, and tissue integration of protein-based medical devices. To address this limitation, we established and applied a six-tiered, stepwise immunological evaluation framework in an appropriate murine model, aiming to systematically characterize the immunological risks of proteinaceous biomaterials. This framework sequentially incorporates baseline immune screening, marketed product comparison, interspecies differentiation, dose–response validation, temporal dynamics assessment, and delayed response detection. By integrating multiple dimensions of readouts, including antibody levels (IgG, IgM, IgA), cytokine profiles (IL-2, IL-6, IL-12p70, IFN-γ, TNF-α), complement activation (C3, C4, C5), immune cell phenotyping, and splenic lymphocyte functionality, the framework establishes a structured, quantifiable, and scalable evaluation pathway. Using recombinant human collagen for injectable fillers as a model material, we demonstrated that this strategy effectively distinguishes diverse immune response types and differentiates material-intrinsic effects from interspecies artifacts, thereby confirming its applicability and interpretive strength in immunological safety assessment of protein-based biomaterials. Collectively, the proposed six-tiered evaluation strategy not only overcomes the limitations of traditional single-parameter or short-term assessments, but also provides a scientifically rigorous and systematic methodology that can serve as a versatile tool for both immunological evaluation and design validation of protein-based and other complex biomacromaterials.

Keywords

Recombinant collagen / Immunological safety evaluation / Layered progressive evaluation framework

References

[1] Jie IWK, Lee KWA, Yoon SE. Advancements in clinical utilization of recombinant human collagen: an extensive review. Life, 2025, 15(4): 582

[2] Sun W, Shahrajabian MH, Ma K, Wang S. Advances in molecular function and recombinant expression of human collagen. Pharmaceuticals, 2025, 18(3): 430

[3] Cao L, Zhang Z, Yuan D, Yu M, Min J. Tissue engineering applications of recombinant human collagen: a review of recent progress. Front Bioeng Biotechnol, 2024

[4] Wosicka-Frąckowiak H, Poniedziałek K, Woźny S. Collagen and its derivatives serving biomedical purposes: a review. Polymers, 2024, 16(18): 2668

[5] Liu W, Lin H, Zhao P, et al.. A regulatory perspective on Recombinant collagen-based medical devices. Bioactive Mater, 2022, 12: 198-202

[6] Yang Y, Yu T, Tao M. Development of recombinant human collagen-based porous scaffolds for skin tissue engineering: enhanced mechanical strength and biocompatibility. Polymers, 2025, 17(3): 303

[7] Lian H, Liu Y, Ke L, Han Q. Deciphering Immunotoxicity in animal-derived biomaterials: a genomic and bioinformatics approach. Int J Mol Sci, 2024, 25(20): 10963

[8] GB/T 16886.20–2015:Biological evaluation of medical devices—part 20: principles and methods for immunotoxicology testing of medical devices.

[9] Chandrasekar V, Panicker AJ, Dey AK, et al.. Integrated approaches for immunotoxicity risk assessment: challenges and future directions. Discover Toxicol, 2024, 1(1): 9

[10] Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res, 2011, 28(10): 2379-85

[11] Yong KSM, Her Z, Tan SY. Humanized mouse as a tool to predict immunotoxicity of human biologics. Front Immunol, 2020

[12] Guo X, Ma Y, Wang H. Status and developmental trends in recombinant collagen preparation technology. Regen Biomater, 2023

[13] Kumar D, Romero Y, Schuck KN, Smalley H, Subedi B, Fleming SD. Drivers and regulators of humoral innate immune responses to infection and cancer. Mol Immunol, 2020, 121: 99-110

[14] Gong S, Ruprecht RM. Immunoglobulin M: an ancient antiviral weapon – rediscovered. Front Immunol, 2020

[15] Jones K, Savulescu AF, Brombacher F, Hadebe S. Immunoglobulin M in health and diseases: how far have we come and what next?. Front Immunol, 2020

[16] Carvalho Á, Henriques AR, Queirós P. Persistence of IgG COVID-19 antibodies: a longitudinal analysis. Front Public Health, 2023

[17] Dan JM, Mateus J, Kato Y, et al.. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 2021, 371(6529): eabf4063

[18] Pracht K, Wittner J, Kagerer F, Jäck H-M, Schuh W. The intestine: a highly dynamic microenvironment for IgA plasma cells. Front Immunol, 2023

[19] Gao P, Morita N, Shinkura R. Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers. Semin Immunopathol, 2024, 47(1): 1

[20] Zhou X, Wu Y, Zhu Z, et al.. Mucosal immune response in biology, disease prevention and treatment. Signal Transduct Target Therapy, 2025, 10(1): 7

[21] Akkaya M, Kwak K, Pierce SK. B cell memory: Building two walls of protection against pathogens. Nat Rev Immunol, 2020, 20(4): 229-38

[22] Hunt RM, Elzayat MT, Markofski MM, Laughlin M, LaVoy EC. Characterization of transitional memory CD4 + and CD8 + T-cell mobilization during and after an acute bout of exercise. Front Sports Act Living, 2023

[23] Seder RA, Ahmed R. Similarities and differences in CD4 + and CD8 + effector and memory T cell generation. Nat Immunol, 2003, 4(9): 835-42

[24] Sckisel GD, Mirsoian A, Minnar CM, et al.. Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. J Immunother Cancer, 2017, 5(1): 33

[25] Zhuang Z, Chen Y, Liu Z, Fu Y, Wang F, Bai L. Pharmacological validation of a novel exopolysaccharide from Streptomyces sp. 139 to effectively inhibit cytokine storms. Heliyon, 2024

[26] Thomas AM, Chaban V, Pischke SE, et al.. Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically. Mol Immunol, 2022, 141: 273-9

[27] van Brandwijk RJMGE, Michels MAHM, Rossum M. Pitfalls in complement analysis: a systematic literature review of assessing complement activation. Front Immunol, 2022

[28] Borghans JAM, Taams LS, Wauben MHM, de Boer RJ. Competition for antigenic sites during T cell proliferation: A mathematical interpretation of in vitro data. Proc Natl Acad Sci, 1999, 96(19): 10782-7

[29] Staveley-O’Carroll K, Sotomayor E, Montgomery J, et al.. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci, 1998, 95(3): 1178-83

[30] Coss SL, Zhou D, Chua GT, et al.. The complement system and human autoimmune diseases. J Autoimmun, 2023, 137: 102979

[31] Fontes JA, Barin JG, Talor MV, et al.. Complete freund’s adjuvant induces experimental autoimmune myocarditis by enhancing IL-6 production during initiation of the immune response. Immun Inflamm Dis, 2017, 5(2): 163-76

[32] González-Chávez SA, Chaparro-Barrera E, Alvarado-Jáquez MF, Cuevas-Martínez R, Ochoa-Albíztegui RE, Pacheco-Tena C. Complete freund’s adjuvant induces a fibroblast-like synoviocytes (FLS) metabolic and migratory phenotype in resident fibroblasts of the inoculated footpad at the earliest stage of adjuvant-induced arthritis. Cells. 2023;12(6):842. .

[33] McMahan RS, Birkland TP, Smigiel KS, et al.. Stromelysin-2 (MMP10) moderates inflammation by controlling macrophage activation. J Immunol, 2016, 197(3): 899-909

[34] Chien C-H, Chiang B-L. Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells. J Biomed Sci, 2017, 24(1): 86

[35] Kong Y, Tang W, Kang H, et al.. Linear and non-linear proteome-wide association studies provide novel insight into venous thromboembolism. Nat Commun, 2025, 16(1): 6517

[36] Daood NJ, Russo DP, Chung E, Qin X, Zhu H. Predicting chemical immunotoxicity through Data-Driven QSAR modeling of Aryl hydrocarbon receptor agonism and related toxicity mechanisms. Environ Health (Wash), 2024, 2(7): 474-85

Funding

National Key R&D Program of China(2024YFC2420800)

Beijing Natural Science Foundation(L244001)

Jiangsu High-level Innovative and Entrepreneurial Talents(JSSCRC2024490)

China NMPA Research on performance and safety evaluation of innovative biomaterial medical devices(RS2024X004)

RIGHTS & PERMISSIONS

The Author(s)